色情報の可触化手法の研究

電気通信大学201

ブラウン運動論と量子力学(II)

この論文は国立情報学研究所の電子図書館事業により電子化されました

副作用自発報告データベース及び医療情報データベースを用いた、デノスマブによる低カルシウム血症に関する、発症例の検出及び行政施策の影響評価

Tohoku University齋藤嘉朗課

ライフログを活用した実世界指向ゲームの作成と記憶想起実験による評価

電気通信大学200

ESTRAMUSTINE PHOSPHATE THERAPY IN CARCINOMA OF THE PROSTATE

Effects of estramustine phosphate (Estracyt/, EMP) were studied in 20 patients with •advanced carcinoma of the prostate. Ten patients received no treatment before EMP-therapy(study I), and the other 10 patients received previous estrogen-therapy (study II). Some of the latter cases showed resistance to estrogen-therapy immediately, and the others suffered relapses after varying periods of remission. In study I, EMP showed 75% .improvement of subjective symptoms (dysuria, urination frequency and pain), and 88% of objective signs (residual urine, palpation of the prostate and serum prostatic acid phosphatase). In study II, it showed 25% improvement of subjective symptoms and 60% of objective signs. Comprehensive evaluation showed that the effectiveness of EMP on prostatic carcinoma was 90% in study I, and 50% in study II. The effectiveness of EMP closely related to the duration of the remission elicited by preceding estrogen-therapy. In cases where the remission was less than 2 years, the effectiveness of EMP was 90-100%. However, if the remission was more than 2 years, it was only 17%. From these results, it was concluded that EMP should be administered as a first choice drug